Little information is available concerning molecules that regulate the growth of human mammary carcinoma cells. The lack of success in this field may be in part attributed to an approach that has relied heavily upon attempts to use xenogenic monoclonal antibodies as probes to identify such molecules (Ceriani et al., 1977; Herylyn et al., 1980; Minna et al., 1981) . Xenogenic species are likely to evoke immune response preferentially to immunologically dominant antigens. The generation of monoclonal antibodies that detect functionally relevant molecules may be hindered by the production of multiple antibodies to such immunogenically dominant antigens in human cell preparations used for immunisation in the mouse.
An alternative to the above approach is the use of human monoclonal antibodies as probes to identify functional molecules of breast carcinoma cells. The rationale for the use of human monoclonal antibodies is as follows. The existence of mammary tumour associated antigens (TAA) has been documented (Colcher et al., 1981; Soule et al., 1983) . Such antigens produced by malignant cells may induce an immune response in the host, leading to the production of autologous antibodies in patients with cancer. Indeed, the presence of antibodies which bind to allogeneic tumour cells in tissues has been found in sera of patients with mammary carcinomas (Cote et al., 1983; Schlom et al., 1990; Sikora & Wright, 1981) . Encouraged by such reports, studies were initiated which utilised lymphocytes obtained from involved lymph nodes from patients with metastatic carcinomas as fusion partners in the hybridoma technique (Christensen et al., 1986; Cote et al., 1983; Haspel et al., 1985; Imam et al., 1985; Imam & Taylor, 1989; Lowe et al., 1984; Schlom et al., 1980; Sikora & Wright, 1981) . This approach appears to offer an excellent prospect of obtaining lymphocytes sensitised against tumour-associated antigens, hence obtaining the relevant human monoclonal antibodies by selection of suitable hybrids. Initial difficulties in obtaining hybrid clones that are stable in secreting human monoclonal antibodies have mostly been overcome (Christensen et al., 1986; Haspel et al., 1985; Imam et al., 1985; Imam & Taylor, 1989; Lowe et al., 1984) . Similarly, the technical difficulties of studying the specificity and patterns of distribution of antigens that are rew..ognised by these antibodies in human tissues have also been resolved (Christensen et al., 1986; Haspel et al., 1985; Imam et al., 1985; Imam et al., 1986a; Imam & Stephanian, 1988; Imam & Taylor, 1989; Starling et al., 1988) . Antibodies thus generated have shown quantitative differences between malignant and normal epithelial cells, as evidenced by differences in tissue staining using immunohistochemical methods (Haspel et al., 1985; Imam et al., 1985; Imam & Taylor, 1989) . However, the structural and functional properties of antigens recognised by these antibodies have not yet been reported. This paper reports the application of a human monoclonal antibody (IgG2, kappa-light chain) as a probe to purify and characterise an antigen, that is secreted at elevated levels by oncogenically transformed or established lines of mammary carcinoma cells (both being tumourigenic), compared with immortalised (non-tumourigenic) counterparts. The antigen was purified to homogeneity from both the malignant and immortalised mammary epithelial cells. Two forms, termed TAA.62(T-from tumourigenic cells) and TAA.62(I-from immortalised cells) were purified from the conditioned medium from the malignant cell line (MDA.MB.231) and immortalised (184A1) mammary epithelial cells respectively. The antigen TAA.62(T) purified from the conditioned-medium of malignant cells interacted specifically with an association constant of 16.6 nM with the in vitro a cell surface receptor of 160 kilodaltons from malignant as well as the immortalised cells. However, the antigen [TAA.62(I)J purified from the conditioned-medium of the immortalised cells failed to interact with the 160 kd molecule. The binding of antibody to malignant cells in vitro inhibited the proliferation of the cells.
Materials and methods

Cell lines
The established cell lines employed in this study were Hammond et al. (1984) and Clark et al. (1988) . The immortalised cell line (184A1) is non-tumorigenic whereas the oncogenically transformed (184AIN4-T-D1O) mammary epithelial cell line is highly tumourigenic in nude mice (Clark et al., 1988) . The cells were grown as described by Hammond et al. (1984) and Clark et al. (1988) Generation and purification human monoclonal antibody Lymphocytes from the lymph node of a patient with metastatic mammary carcinoma were fused with a non-secreting variant of murine myeloma cells and one antibody was selected, purified and labelled with biotin as described previously (Imam et al., 1985; Imam & Taylor, 1989) . The antibody was termed anti-TAA.62 (Tumour Associated Antigen) to indicate its predominant reactivity and the apparent molecular weight of antigen recognised. F(ab')2 fragments of the antibody were prepared according to the method of Parham (1983) . Both the whole and F(ab')2 fragments of anti-TAA.62 were sterilised by filtration before use.
Immunochemical method of staining Normal and neoplastic human tissues were obtained from the surgical pathology files of Los Angeles County/University of Southern California Medical Center. Tissues used were either frozen in liquid nitrogen or fixed in formalin. Tissues were sectioned at 5 gsm, and representative sections were stained with haematoxylin and eosin to confirm the diagnosis prior to immunoperoxidase staining. Staining observed in frozen and formalin paraffin sections was similar quantitatively and qualitatively, leading to a preference in the latter, because of superior morphology. Fifty or 100 fLl of biotinylated human monoclonal antibody (10;Lgml-') were applied directly to cytocentrifuge preparations of cells or tissue sections. Otherwise the immunohistochemical method was as described previously (Imam et al., 1985; Imam & Taylor, 1989) . Biotinylated primary antibody preabsorbed with the purified TAA.62 served as a negative control. Histological classifications of breast cancer tissue was determined according to Bloom and Richardson (1975) .
Comparison of epitopes
Competitive immunocytochemically steric-inference assays were performed using immunocytological techniques in order to investigate the nature of the epitopes recognised by anti-TAA.62 antibody in relation to epitopes recognised by previously generated human monoclonal antibodies (Imam et al., 1985; Imam & Taylor, 1989 (Imam et al., 1985; Imam & Taylor, 1989) , followed by incubation with biotinylated antibody to TAA.62. The remainder of the staining procedure was as described previously (Imam & Taylor, 1989 Immunoprecipitation of radiolabelled cell extract with human monoclonal antibody The cell extracts or the concentrated conditioned media were radioiodinated as described previously (Imam, 1986) . 1251I labelled proteins from the NP-40 extracts of the established (MDA.MB.231 and MCF.7), the oncogenically transformed (184AlN4-T-D10) or the immortalised (184A1) mammary epithelial cell lines (approximately 400 ng of protein containing 5 x I0' c.p.m.) were mixed with 1001l of either anti-TAA.62 antibody (1.0 mg ml-') or anti-TAA.62 antibody preabsorbed with purified antigen (TAA.62). The latter antibody served as a negative control. In addition, concentrates of the conditioned media resulting from the cultures of the above cell lines were also immunoprecipitated with the human monoclonal antibody as described. The mixture was incubated overnight at 4°C. Following the incubation, a 1001l suspension of Sepharose 4B conjugated to goat antihuman IgG was added to each reaction mixture. The sample was incubated for a further period of 60 min and centrifuged at 5,000 g for 5 min. Following the removal of superna tant by aspiration, the pellet was washed five times with 0.05 M NaCl, 1.0% (w/v) ovalbumin and 0.05% (v/v) NP-40 to remove any non-specifically bound radioactivity. The immunoprecipitates were separated by SDS-PAGE and were visualised by autoradiography (Imam & Taylor, 1989; Laemmli, 1970 ).
Purification of TAA.62
All manipulations during the experiment were carried out at 4°C unless otherwise stated. A column (0.6 cm x 10.0 cm) was packed with anti-TAA.62 covalently coupled to CNBractivated Sepharose 4B as described previously (Murphy et al., 1976 (Staros, 1982) was used in these studies. For these experiments, the established (MDA.MB.231) or the immortalised (184A1) cell lines were grown in 60 mm dishes as described above for the binding experiments. The monolayers were washed three times with EBSS-Hepes 0.1 mg ml-l BSA (washing buffer) and then incubated at 4°C for 30 min with 6 nM '251I-labelled TAA.62-(T) or TAA.62(I) in 0.5 ml of the washing buffer in the presence or absence of 0.3 lLM unlabelled TAA.62(T) or TAA.62(I). The monolayers were then washed four times with cold EBSS-Hepes. Cross-linking was initiated by the addition of freshly prepared 5 mM bis(sulfoxuccinimido)suberate (BS3) in 0.5 ml of cold EBSS-Hepes. After a 10 min incubation at 4°C, the monolayers were washed thrice with EBSS-Hepes, solubilised with 50 yl of SDS sample buffer and then subjected to SDS gel electrophoresis and autoradiography.
Effects of human monoclonal antibody on cell growth In order to assess the effects of anti-TAA.62 antibody on the in vitro cell growth, the established (MDA.MB.231 and MCF.7), the oncogenically transformed (184AlN4-T-D1O) or the immortalised (184A1) cell lines were cultured at a density of 5 x 104 cells per 35 mm petri dish in 3 ml of the appropriate medium of 37°C in a humidified atmosphere containing 5% CO2. The cultures were continued for 96 h in the presence of various concentrations, ranging from 0.1 to 6.4 ytg ml-', of intact or F(ab')2 fragment of the antibody, or with antibody preabsorbed with purified antigen (control). In addition, TAA.62-negative cell lines, including renal carcinoma (SW156) and liver carcinoma cell (SK-HEP-1) lines, were studied under identical conditions as controls. Following the incubation period, the number of viable cells in each dish was counted using trypan blue dye exclusion limit on a haemacytometer for the determination of optimum concentrations needed for the antibody. Subsequently, the above cell lines were cultured in the appropriate medium in the presence of the predetermined optimum concentration of F(ab')2 fragments of anti-TAA.62 antibody as described above. The number of viable cells in each dish was determined at intervals of 24 h for 5 days. (Imam et al., 1985; Imam & Taylor, 1989) . Use of a direct method is of a paramount importance since indirect immunohistological methods, attempting to localise HMAb applied to human tissues suffer from an inherent problem of detecting not only the HMAb but also endogenous immunoglobulin. To overcome this difficulty, a direct method was developed which utilised biotinylated primary antibody and avidin-biotin-peroxidase complex (Imam et al., 1985; Imam et al., 1986 (Figure 2b ). The cell lines derived from cervix, colon, lung, pancreas and stomach also showed reactivity with the antibody (Table II) Comparison was made between epitopes recognised by anti-TAA.62 antibody with those of the previously generated human monoclonal antibodies (Imam et al., 1985; Imam & Taylor, 1989 A-D). The results suggest that the antigens from different sources as recognised by the antibody are identical in terms of their molecular weight. Avoidance of reduction of the extract before electrophoresis had no effect on the migration of the antigen (result not illustrated). Application of the antibody preabsorbed with the purified preparation of TAA.-62(T) showed no reactivity with the conditioned-medium from the immortalised cells (184A1) or the established cell line (MDA.MB.231) (Figure 4, lanes E, F) . Conversely, the application of the antibody preabsorbed with TAA.62(I) also exhibited no reactivity with the above sources (results not illustrated).
Conditioned-medium from cultures of the immortalised cells (184A1) or the established cell line (MDA.MB.231) were used as source to purify TAA.62. One litre of the concentrated conditioned medium from the above sources was separately applied to a column (0.6 cm x 10 cm) packed with anti-TAA.62 conjugated to CNBr activated Sepharose 4B. The specifically bound material from the immobilised antibody was eluted with 0.1 M Gly/HCI buffer, pH 3.3 ( Figure  5 ). The specifically eluted material consisted mostly of TAA.62, with small traces of components with high molecular weight, as revealed by SDS-PAGE analysis (results not shown).
Subsequently, the fractions resulting from the above immunoaffinity column and containing TAA.62 from the MDA.MB.231 cell line, or the immortalised mammary epithelial cells (184A1), were separately chromatographed on a column packed with Sephadex-G150. An elution profile using material of MDA.MB.231 is illustrated in Figure 6 . Approximately 90% of the total protein applied was eluted in fractions 56 to 59. Twenty sg of protein eluted at this peak from both sources was separately radioiodinated and a portion of each was analysed by SDS-polyacrylamide gel electrophor- Fraction no.
Figure 6 Sephadex G-150 chromatography of the specifically bound material from immobilised anti-TAA.62. Sample (bound material from anti-TAA.62-Sepharose 4B column) was applied to a column (1.5 cm x 90cm) of Sephadex G-150 in 0.05 M Tris HCI buffer, pH 7.5, containing 0.15 M NaCl, 5 mM EDTA and 0.05% (v/v) NP-40, which also served as the running buffer. The column flow rate was 5.0 ml h'. Fractions (1.0 ml) were collected and optical density at 280 rm of each measured on a spectrophotometer. Fractions taken for further analysis are designated '1'. esis, followed by autoradiography. The protein eluted at this peak yielded a single band with an apparent molecular weight of 62 kilodaltons on SDS-polyacrylamide gel electrophoresis as visualised by autoradiography (Figure 7 ). TAA.62 preparations purified under similar conditions from immortalised breast cells, or the MDA.MB.231 cell line, were identical with respect to molecular weight. Furthermore, absorption of anti-TAA.62 with either purified preparations led to the abolition of the immunoreactivity of the antibody (Figure 3 , lanes E and F).
Comparison with other known growth factors
Other known growth factors, such as transforming growth factor-z (TGF-z), TGF-P, epidermal growth factor (EGF), insulin-like growth factor (IGF) or insulin, which are known to interact with these cells were incorporated in the study. The target cells were grown as described. Subsequently, the cells were washed ando the cellular binding assay using 12511
labelled TAA.62(T) was performed in the presence or absence of TGF-xo, TGF-P, EGF, IGF or insulin under the identical conditions. These growth factors were unable to compete with the '25I-labelled TAA.62(T), even at micromolar concentration (Table III) A portion of material eluted from the Sephadex G-150 column (please see Figure 6 ) was labelled with 1251 and analysed by SDS-polyacrylamide gel electrophoresis as described in the text. Following the electrophoresis, one gel was frozen and sliced into 1.0 mm thickness and the radioactivity of each slice was counted on a gamma counter, whereas the other gel was subjected to autoradiography and is inserted at the top of the illustration. Figure 11 . The petri dish that received the preabsorbed anti-TAA.62 antibody or an irrelevant human monoclonal antibody of the same immunoglobulin class, HMA.31 (Imam & Taylor, 1989) (Christensen et al., 1986; Cote et al., 1983; Haspel et al., 1985; Imam et al., 1985; Imam & Taylor, 1989; Lowe et al., 1984; Schlom et al., 1980; Sikora & Wright, 1981 (Table  I) . However, as in breast, the level of expression of the antigen was much higher in malignant cells, as compared to their normal counterparts, again suggesting an association of increased levels with malignancy.
The pattern and intensity of staining of cultured mammary epithelial cells was remarkably similar to findings in tissues. Immortalised cells (184A1), that are non-tumourigenic in nude mice, showed a weak reactivity: a detailed characterisation of these cells has been described by Clark et al. (1988) . Conversely, malignant mammary epithelial cells, derived from the established cell lines or from oncogenically transformed (184AIN4-T-D10) cells, contained elevated levels of the antigen in the cytoplasmic compartment: these cell types are tumourigenic in nude mice (Clark et al., 1988 immortalised cells. Studies to determine the structural difference between TAA.62(T) and TAA.62(I) and the significance of interaction between TAA.62(T) and 160 kd receptor on the proliferation of malignant breast cells are the subjects of continuing investigation.
